Biogen Pills - Search News

Biogen, felzartamab and Phase 3 Study

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

PMLive · 1d

Biogen initiates phase 3 study of felzartamab in kidney transplant patients

Beyond AMR, Biogen is planning to initiate phase 3 trials of felzartamab in two kidney diseases, IgA nephropathy and primary membranous nephropathy, in 2025.

Markets Insider · 3d

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a

Pharmabiz · 1d

Biogen begins TRANSCEND phase 3 study of felzartamab to treat late antibody-mediated rejection in kidney transplant patients

Cambridge, Massachusetts Thursday, March 13, 2025, 10:00 Hrs [IST]

Zacks.com on MSN · 2d

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

Biogen BIIB announced that dosing has begun in a phase III study evaluating its key pipeline candidate, felzartamab, in adult kidney transplant recipients diagnosed with late antibody-mediated rejection (AMR).

14don MSN

EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

3don MSN

Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed

Sage Therapeutics (NASDAQ:SAGE) stock drops as Bank of America issues an Underperform rating citing an end to Biogen's (BIIB) ...

BioPharma Dive2d

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

Decoding Biogen's Options Activity: What's the Big Picture?

Today, Benzinga 's options scanner spotted 32 uncommon options trades for Biogen. This isn't normal. The overall sentiment of these big-money traders is split between 37% bullish and 31%, bearish. Out ...

pharmaphorum8d

NICE agrees to look again at Alzheimer's drug Leqembi

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Biogen announces initiation of dosing in TRANSCEND

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

4BIIB, LLY : Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed...

NICE has upheld its decision not to recommend Alzheimer's treatments donanemab and lecanemab for NHS use, citing high costs ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results